{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.5","upperLimit":"66.7","value":"51.2"},{"groupId":"OG001","lowerLimit":"35.8","upperLimit":"66.3","value":"51.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with a PR or better based on IMWG criteria. Per IMWG criteria, PR was defined as ≥50% reduction of serum M-protein plus reduction in 24-h urinary M-protein by ≥90% or to \\<200 mg per 24 h. In addition to these criteria, if present at baseline, a ≥50% reduction in the size (SPD) of soft tissue plasmacytomas was also required.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with anti-CD38 mAb-naive RRMM received daratumumab at a dose of 1,800 mg by subcutaneous (SC) injection in 28-day treatment cycles.","id":"OG000","title":"RRMM Expansion Part B: Daratumumab"},{"description":"Participants with anti-CD38 mAb-naive RRMM received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day treatment cycles.","id":"OG001","title":"RRMM Expansion Part B: GEN3014"}],"paramType":"NUMBER","populationDescription":"Full Analysis set included all enrolled participants who received at least 1 dose of trial drug (GEN3014 or daratumumab SC).","reportingStatus":"POSTED","timeFrame":"Up to approximately 4 years 3 months","title":"Expansion Part B: ORR","type":"PRIMARY","unitOfMeasure":"percentage of participants"}